MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MIRM had $53,899K increase in cash & cash equivalents over the period. $39,494K in free cash flow.

Cash Flow Overview

Change in Cash
$53,899K
Free Cash flow
$39,494K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
2,905 -20,538
Stock-based compensation
18,127 34,271
Depreciation and amortization
6,062 12,108
Inventory reserves and firm commitment losses
-540 -2,349
Amortization of debt discount and offering costs
443 860
Unrealized foreign exchange gain
643 1,270
Non-cash lease expense
447 826
Other
345 674
Accounts receivable
3,146 25,901
Prepaid and other current assets
4,632 7,114
Inventory
1,159 5,007
Other assets
2,684 1,342
Accounts payable, accrued expenses and other liabilities
24,346 22,314
Operating lease liabilities
-580 -803
Net cash provided by operating activities
39,681 10,079
Purchase of investments
20,860 65,063
Proceeds from maturities of investments
18,820 42,497
Purchase of property and equipment
187 167
Payments made for additions to intangible assets
0 0
Net cash used in investing activities
-2,227 -22,733
Proceeds from issuance of common stock pursuant to equity plans
16,096 15,047
Net cash provided by financing activities
16,096 15,047
Effect of exchange rate on cash, cash equivalents and restricted cash
349 3,281
Net increase (decrease) in cash, cash equivalents and restricted cash
53,899 5,674
Cash and cash equivalents at beginning of period
222,928 -
Cash and cash equivalents at end of period
282,501 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals, Inc. (MIRM)